Efficacy and safety of split-dose ultra-low-volume polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate for bowel preparation: a systematic review and meta-analysis.

Eur J Gastroenterol HepatolFeb 24, 2026 (epub)
Clinical ResearchGastroenterology

Abdallfatah Abdallfatah, Ahmed W Hageen, Dania Albader et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared split-dose ultra-low-volume polyethylene glycol with ascorbic acid (PEG + Asc) against sodium picosulfate with magnesium citrate for colonoscopy bowel preparation. Six studies involving 3285 patients were included. Overall and right-sided colon adequate cleansing rates did not differ significantly between regimens (risk ratios 1.05 and 1.03, respectively). PEG + Asc was associated with a significantly lower vomiting rate, while nausea, abdominal pain, and overall Boston Bowel Preparation Scale scores showed no significant differences. Evidence quality varied across outcomes.

Key findings

  • Overall adequate cleansing did not differ significantly: risk ratio 1.05, 95% CI: 0.99-1.12, P = 0.1082.
  • Right-sided colon adequate cleansing did not differ significantly: risk ratio 1.03, 95% CI: 0.99-1.08, P = 0.1755.
  • PEG + Asc had a significantly lower vomiting rate than sodium picosulfate with magnesium citrate (risk ratio: 2.58, 95% CI: 0.94-2.78, P = 0.0008).
  • Nausea, abdominal pain, and overall Boston Bowel Preparation Scale scores showed no significant differences.

Why it matters

Adequate bowel cleansing is important for colonoscopy, and these pooled findings suggest that both regimens provide comparable overall and right-sided cleansing. The lower vomiting rate reported with PEG + Asc may be relevant when considering tolerability. However, evidence quality varied, so the findings should be interpreted cautiously rather than treated as definitive evidence of superiority.

What to keep in mind

The review included six studies, and the authors report that evidence quality varied across outcomes.

Source

Published in Eur J Gastroenterol Hepatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.